Johnson & Johnson won U.S. approval for a daily psoriasis pill that rivals the benefits of injectable medicines and could disrupt a multibillion-dollar market. The approval marks the first oral treatment of its kind for psoriasis patients.
The new pill represents a significant development in psoriasis treatment, offering patients an alternative to current injectable therapies. Oral medications typically provide greater convenience and potentially better patient compliance compared to injectable treatments.